

Cincata







Cincata

For Blood Sugar Management

Diabetes is a disorder in humans or animals characterized by high glucose levels in the blood after eating or prolonged fasting due to reduced secretion or functioning of hormone, Insulin. The rise in the blood glucose can be attenuated at two levels, one by altering the speed with which the food is digested and absorbed into the blood (postprandial) and secondly, by mobilizing the extra glucose present in the blood to peripheral tissues like muscle and fat tissues or liver or channeling the glucose to the oxidation for energy (physical exercise).

Type-2 diabetes represents a serious threat to the health of the population of almost every country in the world. The World Health Organization estimates that 1.1 million people died as a result of diabetes in 2005, and this is almost certainly an underestimate. Moreover, the figure is expected to increase by 50% during the next ten years. This escalation is due in part to increasing rates of childhood obesity. Until recently, type-2 diabetes was a disease that afflicted only adults. Now a growing number of children are being diagnosed with obesity related type-2 diabetes. There is, therefore, an urgent need for new approaches to address obesity and type-2 diabetes and their associated complications



Cincata[™]

TABLE OF CONTENTS

Cincata [™] Scientific Perspective	04
Cincata [™] Developmental Strategy	0;
Origin of Cincata™	06
Pharmacognosy	06
How Cincata™ works	07
Cincata [™] Standardization: Metabolite Fingerprinting	08
In vitro assays on Cincata™	08
Efficacy of Cincata™	08
Safety of Cincata™	10
Patent and Trademark	10
Manufacturing of Cincata™	11
Cincata [™] For Healthy Blood Sugar Management	1:
References	12

Cincata[™] promotes healthy sugar balance in diabetes by improving insulin activity

Scientific Perspectives

Cincata[™] helps to maintain healthy blood glucose from impaired glucose tolerance and hyperglycemic condition by a) inhibiting the enzymes involved in the metabolism of carbohydrates in intestine, b) enhancing the functioning of insulin in muscle and liver cells and c) inhibiting the enzyme dipeptidyl peptidase-4, which is involved in metabolism of incretin hormone, glucagons like peptide-1 (GLP-1) responsible for insulin activity as well as satiety signaling. Cincata[™] intervention in streptozotocine induced diabetic SD rats reduced the level of glycated hemoglobin level by 55% compared to diabetic control animal from their baseline.

The safety and toxicity studies showed that Cincata[™] is non-toxic to rats at dose levels of 2000 mg/kg body

weight and 5000 mg/kg body weight. Therefore, the LD₅₀ of CincataTM is expected to exceed 5000-mg/kg body weight. The repeated dose 28-day oral toxicity study in rats indicated that CincataTM had no adverse effect on general health, growth, haematological, clinical chemistry, organ weights and gross appearance of the tissues / organs of the rats treated at and up to the dose level of 1000 mg/kg body weight. The genotoxicity toxicity (AMES test) study on CincataTM did not show any mutagenic potential in Salmonella typhimurium.

Cincata[™] is a very safe and potent blood sugar modulator with multi target activity and can be used to manage healthy blood sugar levels from impaired glucose tolerance and hyperglycemic condition.

Avesthagen Limited 05

Cincata™ - Developmental Strategy

